38 results on '"Falter, Tanja"'
Search Results
2. A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
3. Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura
4. Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19
5. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura
6. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura
7. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
8. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
9. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
10. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies
11. Prevalence of overweight and obesity, its complicationscomplications and progression in a 10-year follow-up in the Gutenberg Health Study (GHS).
12. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
13. Prevalence of Overweight and Obesity, Its Complications, and Progression in a 10-Year Follow-Up in the Gutenberg Health Study (GHS).
14. One fits all: a highly sensitive combined ddPCR/pyrosequencing system for the quantification of microchimerism after hematopoietic and solid organ transplantation
15. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels
16. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
17. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey
18. Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals
19. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report
20. Association of Specific Antiphospholipid Antibodies to Platelet Count and Thrombocytopenia
21. Influence of Thrombotic Thrombocytopenic Purpura on Depressivity, Cognitive Conduction, Quality of Life, and Resilience of Patients
22. Comment on 'Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States'
23. Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker
24. No Evidence for Classic Thrombotic Microangiopathy in COVID-19
25. Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura
26. BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response
27. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab
28. Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura
29. Untersuchungen über ADAMTS13 in Gerinnungsfaktorpräparaten
30. Elevated risperidone serum concentrations during acute inflammation, two cases
31. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels
32. Prevalence and type of potential pharmacokinetic drug-drug interactions in old aged psychiatric patients
33. Gerinnungsdiagnostik – Hämostasestörungen erkennen
34. Investigation of Side Effects of Plasmaexchange In the Treatment of Thrombotic Thrombocytopenic Purpura
35. ADAMTS13 In 4 Different VWF/VIII Concentrates and Its Impact on Therapy.
36. Evaluation of Clotting Factor Concentrates for Treatment of Thrombotic Thrombocytopenic Purpura.
37. Comment on "Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States".
38. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.